An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
Public ClinicalTrials.gov record NCT04620811. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Open-Label, Extension Study to Evaluate the Efficacy and Safety of AK002 in Patients That Were Previously Enrolled in AK002-016 or AK002-012 Studies and Have Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 3, open-label, extension study to assess the long term efficacy and safety of lirentelimab given monthly.
Study identification
- NCT ID
- NCT04620811
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 159 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 3, 2020 (Actual)
- Primary completion
- May 15, 2023 (Actual)
- Completion
- Jul 7, 2023 (Actual)
- Last update posted
- Apr 22, 2024
2020 – 2023
United States locations
- U.S. sites
- 38
- U.S. states
- 19
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Allakos Investigational Site 216-068 | Birmingham | Alabama | 35209 | — |
| Allakos Investigational Site 216-002 | Huntsville | Alabama | 35802 | — |
| Allakos Investigational Site 216-035 | Phoenix | Arizona | 85018 | — |
| Allakos Investigational Site 216-032 | Chula Vista | California | 91910 | — |
| Allakos Investigational Site 216-014 | Santa Monica | California | 90404 | — |
| Allakos Investigational Site 216-038 | Tustin | California | 92780 | — |
| Allakos Investigational Site 216-049 | Walnut Creek | California | 94598 | — |
| Allakos Investigational Site 216-034 | Aurora | Colorado | 80045 | — |
| Allakos Investigational Site 216-063 | Brandon | Florida | 33511 | — |
| Allakos Investigational Site 216-027 | Edgewater | Florida | 32132 | — |
| Allakos Investigational Site 216-056 | Jacksonville | Florida | 32256 | — |
| Allakos Investigational Site 216-013 | Miami | Florida | 33176 | — |
| Allakos Investigational Site 216-053 | New Port Richey | Florida | 34653 | — |
| Allakos Investigational Site 216-007 | Chicago | Illinois | 60611 | — |
| Allakos Investigational Site 216-001 | Crowley | Louisiana | 70526 | — |
| Allakos Investigational Site 216-026 | Boston | Massachusetts | 02111 | — |
| Allakos Investigational Site 216-052 | Boston | Massachusetts | 02115 | — |
| Allakos Investigational Site 216-051 | Boston | Massachusetts | 02215 | — |
| Allakos Investigational Site 216-005 | Rochester | Minnesota | 55905 | — |
| Allakos Investigational Site 216-042 | Kansas City | Missouri | 64108 | — |
| Allakos Investigational Site 216-045 | Reno | Nevada | 89511 | — |
| Allakos Investigational Site 216-025 | New York | New York | 10029 | — |
| Allakos Investigational Site 216-020 | Chapel Hill | North Carolina | 27599 | — |
| Allakos Investigational Site 216-048 | Durham | North Carolina | 27710 | — |
| Allakos Investigational Site 216-050 | Winston-Salem | North Carolina | 27157 | — |
| Allakos Investigational Site 216-031 | Cincinnati | Ohio | 45229 | — |
| Allakos Investigational Site 216-028 | Cincinnati | Ohio | 45236 | — |
| Allakos Investigational Site 216-044 | Mentor | Ohio | 44060 | — |
| Allakos Investigational Site 216-021 | Philadelphia | Pennsylvania | 19104 | — |
| Allakos Investigational Site 216-006 | Chattanooga | Tennessee | 37343 | — |
| Allakos Investigational Site 216-003 | Chattanooga | Tennessee | 37404 | — |
| Allakos Investigational Site 216-011 | Chattanooga | Tennessee | 37421 | — |
| Allakos Investigational Site 216-062 | Kingsport | Tennessee | 37663 | — |
| Allakos Investigational Site 216-022 | Austin | Texas | 78742 | — |
| Allakos Investigational Site 216-039 | Ogden | Utah | 84405 | — |
| Allakos Investigational Site 216-030 | Salt Lake City | Utah | 84132 | — |
| Allakos Investigational Site 216-055 | Sandy City | Utah | 84092 | — |
| Allakos Investigational Site 216-064 | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04620811, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 22, 2024 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04620811 live on ClinicalTrials.gov.